PriceTargets.com logo

Genprex - GNPX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 233.33%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.90 As of 03/24/2023 01:00 AM ET
▲ +0.06 (7.14%)

This chart shows the closing price for GNPX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genprex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNPX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNPX

Analyst Price Target is $3.00
▲ +233.33% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genprex in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 233.33% upside from the last price of $0.90.

This chart shows the closing price for GNPX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Genprex.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/30/2023Dawson JamesInitiated CoverageBuy$3.00Low
1/26/2021National SecuritiesInitiated CoverageBuy$7.00High
5/26/2020Noble FinancialReiterated RatingBuy$5.00High
4/22/2020Alliance Global PartnersInitiated CoverageBuyHigh
4/29/2019Noble FinancialInitiated CoverageOutperform ➝ Outperform$5.00High
4/1/2019Maxim GroupDowngradeBuy ➝ HoldLow
11/20/2018Maxim GroupReiterated RatingBuy$3.00Low
9/14/2018Maxim GroupInitiated CoverageBuy$5.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/27/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Genprex logo
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $0.90
Low: $0.80
High: $0.91

50 Day Range

MA: $1.29
Low: $0.76
High: $1.78

52 Week Range

Now: $0.90
Low: $0.74
High: $2.67

Volume

89,438 shs

Average Volume

799,676 shs

Market Capitalization

$43.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Genprex?

The following Wall Street sell-side analysts have issued stock ratings on Genprex in the last twelve months: Dawson James.
View the latest analyst ratings for GNPX.

What is the current price target for Genprex?

1 Wall Street analysts have set twelve-month price targets for Genprex in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 233.3%. Dawson James has the highest price target set, predicting GNPX will reach $3.00 in the next twelve months. Dawson James has the lowest price target set, forecasting a price of $3.00 for Genprex in the next year.
View the latest price targets for GNPX.

What is the current consensus analyst rating for Genprex?

Genprex currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GNPX will outperform the market and that investors should add to their positions of Genprex.
View the latest ratings for GNPX.

What other companies compete with Genprex?

Other companies that are similar to Genprex include Tonix Pharmaceuticals, Mustang Bio, ASLAN Pharmaceuticals, Medicenna Therapeutics and Purple Biotech. Learn More about companies similar to Genprex.

How do I contact Genprex's investor relations team?

Genprex's physical mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company's listed phone number is (877) 774-4679 and its investor relations email address is [email protected] The official website for Genprex is www.genprex.com. Learn More about contacing Genprex investor relations.